Highline Wealth Partners LLC Makes New Investment in Danaher Co. (NYSE:DHR)

Highline Wealth Partners LLC acquired a new stake in shares of Danaher Co. (NYSE:DHR) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 7,384 shares of the conglomerate’s stock, valued at approximately $2,053,000.

Several other institutional investors also recently made changes to their positions in the stock. CarsonAllaria Wealth Management Ltd. acquired a new position in Danaher during the second quarter valued at approximately $25,000. nVerses Capital LLC acquired a new position in shares of Danaher during the 2nd quarter valued at $25,000. Redmont Wealth Advisors LLC purchased a new stake in Danaher during the 1st quarter worth $30,000. MFA Wealth Advisors LLC acquired a new stake in Danaher in the 2nd quarter valued at $51,000. Finally, Financial Connections Group Inc. purchased a new position in Danaher in the second quarter valued at about $51,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on DHR shares. Barclays lowered their target price on Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a research note on Wednesday, October 23rd. Stephens reiterated an “overweight” rating and set a $315.00 price objective on shares of Danaher in a research note on Wednesday, October 23rd. Leerink Partners boosted their target price on shares of Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. UBS Group lowered their price target on shares of Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a report on Wednesday, October 23rd. Finally, TD Cowen boosted their price objective on shares of Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a report on Wednesday, October 23rd. Seven equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $287.28.

Insider Activity

In related news, CFO Matthew Mcgrew sold 16,172 shares of the stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $279.84, for a total value of $4,525,572.48. Following the sale, the chief financial officer now owns 29,407 shares of the company’s stock, valued at $8,229,254.88. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the transaction, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Matthew Mcgrew sold 16,172 shares of the company’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the completion of the sale, the chief financial officer now directly owns 29,407 shares of the company’s stock, valued at $8,229,254.88. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 21,052 shares of company stock valued at $5,878,937. 11.10% of the stock is currently owned by company insiders.

Danaher Trading Up 0.2 %

NYSE DHR opened at $243.12 on Wednesday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. Danaher Co. has a one year low of $188.75 and a one year high of $281.70. The company has a 50-day simple moving average of $268.40 and a 200-day simple moving average of $260.55. The firm has a market capitalization of $180.08 billion, a PE ratio of 41.15, a price-to-earnings-growth ratio of 4.49 and a beta of 0.83.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. The company had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. Danaher’s quarterly revenue was up 3.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.02 earnings per share. On average, equities analysts forecast that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.44%. The ex-dividend date was Friday, September 27th. Danaher’s payout ratio is 18.31%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.